AAPL 165.4 -1.34 (-0.80%)MSFT 106.08 -1.4 (-1.30%)FB 144.04 -1.32 (-0.91%)ZNGA 3.71 +0.04 (+1.23%)NVDA 146.45 -1.46 (-0.99%)WBA 78.69 -0.4 (-0.51%)GOOG 1041.79 -8.01 (-0.76%)PIH 5 -0.12 (-2.34%)
AAPL 165.4 -1.34 (-0.80%)MSFT 106.08 -1.4 (-1.30%)FB 144.04 -1.32 (-0.91%)ZNGA 3.71 +0.04 (+1.23%)NVDA 146.45 -1.46 (-0.99%)WBA 78.69 -0.4 (-0.51%)GOOG 1041.79 -8.01 (-0.76%)PIH 5 -0.12 (-2.34%)

Balance Sheet ABIO Quote ARCA biopha

All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Year 201420152016
CashAndCashEqui 15 39 7
ShortTermInvest 0 0 14
Cash 15 39 21
AccountReceivab 0 0 0
Inventories 0 0 0
DeferredIncomeT 0 0 0
OtherCurrentAss 0 0 0
TotalCurrentAss 15 39 21
PPE 0 0 0
AccumulatedDepr 0 0 0
NetPPE 0 0 0
EquityAndOtherI 0 0 2
Goodwill 0 0 0
IntangibleAsset 0 0 0
OtherLTAssets 1 1 1
TotalNonCurrent 1 1 3
TotalAssets 16 40 25
ShortTermDebt 0 0 0
AccountsPayable 1 0 1
TaxesPayable 0 0 0
AccruedLiabilit 1 1 1
DeferredRevenue 0 0 0
OtherCurrentLia 0 0 0
TotalCurrentLia 1 2 2
Debt 0 0 0
DeferredTaxesLi 0 0 0
DeferredRevenue 0 0 0
OtherLTLiabilit 0 0 0
TotalNonCurrent 0 0 0
TotalLiabilitie 1 2 2
CommonStock 0 0 0
AdditionalPaidI 99 134 135
RetainedEarning -85 -96 -113
AccumulatedOthe 0 0 0
TotalStockholde 15 38 22
TotalLiabilitie 16 40 25
ARCA biopharma Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes ARCA biopharma Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.